

International



Lp(a) Satellite Meeting

From Bench to Bedside
Innsbruck, May 27-28, 2016

Visit <http://lpa.i-med.ac.at>

Final Program

This meeting is a satellite to the 84th EAS Congress to be held in Innsbruck from May 29 – June 1, 2016



Dear Colleagues and Friends,

Fifty years after the first report by Kåre Berg of Oslo, Lp(a) is finally accepted by the scientific community as a causal risk factor for atherosclerosis and cardiovascular diseases. Considering the great interest in Lp(a), it is astonishing how many gaps there are in our knowledge of its biological function and biosynthetic and catabolic pathways. A major obstacle to functional investigation of Lp(a) is the lack of suitable animal models and cell lines. Other, even more burning, questions pertain to the accurate measurement of Lp(a) plasma concentrations and apo(a) isoforms in the clinical laboratory.

Presently, there is no drug on the market that specifically lowers elevated Lp(a) in patients at increased risk for CVD. We therefore look with great hope to the results of clinical trials with new cholesterol-lowering drugs or, even more so, with medications that are specifically directed against Lp(a).

With the current strong interest in Lp(a) research in mind we decided to organize this International Lp(a) Meeting as a satellite to the 84th EAS Congress in Innsbruck and are very grateful to the EAS and its president Alberico Catapano for supporting our initiative for this meeting. We will bring together the leading experts in Lp(a) research, who have promised to share with us their views and their most recent results in order to promote our knowledge of this important risk factor for atherosclerosis.

Innsbruck (<http://www.innsbruck.at/>) is a charming city in the heart of Europe with an abundance of cultural, sightseeing and sports opportunities, not only in winter but all year 'round.

We enthusiastically look forward to the International Lp(a) Satellite Meeting and invite you to share this important event with us.


*Gert M. Kostner
Florian Kronenberg, Hans Dieplinger*

International

Lp(a) Satellite Meeting

From Bench to Bedside

Innsbruck, May 27-28, 2016



Organizing Committee

Chairman

Gert Kostner, Graz, AT



Vice-Chairmen



Hans Dieplinger
Innsbruck, AT



Florian Kronenberg
Innsbruck, AT

Venue

University of Innsbruck
School of Catholic Theology
Karl-Rahner-Platz 3
6020 Innsbruck



Conference Hotel

Hotel Grauer Bär
Universitätsstraße 5-7, 6020 Innsbruck, Austria
<http://www.innsbruck-hotels.at/hotel-grauer-baer>

Local Members

Winfried März, Graz, AT
Gerd Utermann, Innsbruck, AT

International Advisory Board

Alberico Catapano, Milano, IT
M. John Chapman, Paris, FR
Henry N. Ginsberg, New York, USA
Pia Kamstrup, Copenhagen, DK
Marlys Koschinsky, Windsor, CA
Karam Kostner, Brisbane, AUS
Santica Marcovina, Seattle, USA
Sally McCormick, Dunedin, NZ
Børge Nordestgaard, Copenhagen, DK
Sotirios Tsimikas, San Diego, USA
Olov Wiklund, Gothenburg, SE

International Lp(a) Satellite Meeting

PCO

pdl - Dr. Eugen Preuß
Andreas-Hofer-Straße 6 EG, 6020 Innsbruck, Austria
T +43 512 567303
<http://www.congressinfo.net>

Accreditation

This meeting will be submitted for accreditation by the Austrian Medical Association.

Exhibition

A supporting technical-scientific exhibition will be organized.

Conference webpage

Please visit <http://lpa.i-med.ac.at> for further information

Registration fee (in Euro)

	Early Bird	Regular	On Location
AAS students	50,-	50,-	75,-
Students	75,-	100,-	125,-
AAS members	100,-	100,-	125,-
Regular Fee	150,-	200,-	250,-
Social Event	30,-	30,-	30,-

Registration fee includes attendance to the International Lp(a) Satellite Meeting, as well as all coffee breaks. Lunches and the Social Event are not included.

Recipients of the Young Investigator Award participating at the 84th EAS Congress in Innsbruck will have free access to the International Lp(a) Satellite Meeting.

Student status age limit is 35; confirmation of principal investigator is necessary

Deadlines Early Bird Period ends April 6, 2016
Regular Registration ends May 22, 2016

Final Program

- 8:30 – 8:40 **Opening and welcome**
(Gert Kostner, Graz, AT)
- 8:40 – 9:20 **Plenary session**
Chair: Gert Kostner
- Gerd Utermann** (Innsbruck, AT)
50 years of Lp(a) research: what have we learned and where are we going?
- 9:20 – 10:55 **WS1: Biochemistry and Metabolism of Lp(a)**
Chairs: Hans Dieplinger, Sally McCormick
- 9:20 **Marlys Koschinsky** (Ontario, CA)
Structure-function relationships in apo(a): relevance to physiology and pathophysiology
- 9:45 **Gilles Lambert** (Sainte Clotilde, FR)
PCSK9 modulates the secretion but not the cellular uptake of lipoprotein(a) ex-vivo: an effect blunted by alirocumab
- 10:10 **Henry Ginsberg** (New York, USA)
Mechanisms of Lp(a) lowering by anacetrapib, mipomersen and alirocumab
- 10:35 **Hugh R. Barrett** (Perth, AU)
Effect of evolocumab on Lp(a) metabolism in normolipidemic individuals under physiological conditions
- 10:45 **Monika Sharma** (Dunedin, NZ)
Calcium-dependent endocytosis and recycling of lipoprotein(a) in HepG2 cells
- 10:55 – 11:25 Coffee break

- 11:25 – 12:55 **WS2: Genetics of Lp(a)**
Chairs: Florian Kronenberg, Robert Clarke
- 11:25 **Claudia Lamina** (Innsbruck, AT)
Genome-wide association studies on Lp(a) in the general population
- 11:55 **Sally McCormick** (Dunedin, NZ)
Next generation sequencing identifies novel variations within KIV2 of the LPA gene
- 12:25 **Konrad Schmidt** (Innsbruck, AT)
A common African LPA haplotype is associated with short KIV-2 CNV alleles and low Lp(a)
- 12:35 **Guillaume Pare** (Hamilton, CA)
Lipoprotein(a) and risk of myocardial infarction in seven ethnic groups
- 12:45 **Asma Noureen** (Innsbruck, AT)
Significant differentiation in the apo(a)/Lp(a) trait between chimpanzees from Western and Central Africa
- 12:55 – 14:45 Lunch break

13:05 – 14:35 **LUNCH SYMPOSIUM**
A patient centered approach targeting Lp(α) in lipid management

(supported by PACE – The PACE foundation received funding for this session via an unrestricted educational grant from Amgen)

Chairs: Erik Stroes, Henry Ginsberg

13:05 **Henry Ginsberg** (New York, USA)
Introduction

13:15 **Klaus Parhofer** (Munich, DE)
A patient with elevated Lp(α): What is current clinical practice to manage this condition?

13:35 **Sandra Reville Tremulis**
 (Lipoprotein(a) Foundation, San Carlos, CA, USA)
Surviving elevated Lp(α): a patient story from diagnosis to treatment

14:05 **Erik Stroes** (Amsterdam, NL)
The future perspectives for care for patients with high Lp(α)

14:25 **Discussion**

14:45 – 15:55 **WS3: Pathophysiology of Lp(α)**
Chairs: Marlys Koschinsky, Ernst Schaefer

14:45 **Joseph Witztum** (La Jolla, USA)
New evidence on oxidized phospholipids and Lp(α)

15:15 **Siroon Bekkering** (Amsterdam, NL)
Oxidized phospholipids on lipoprotein(α) induce epigenetic reprogramming and an increased pro-atherogenic response in human monocytes

15:25 **Simone Verweij** (Amsterdam, NL)
Oxidized phospholipids on lipoprotein(α) elicit arterial wall inflammation and an inflammatory monocyte response in humans

15:35 **Claes Bergmark** (Stockholm, SE)
The long non-coding RNA MIAT regulates smooth muscle cell proliferation and macrophage activity in advanced atherosclerotic lesions. Correlation with Lp(α)

15:45 **Masayuki Ozawa** (Kagoshima, JP)
Cloned miniature pigs expressing high levels of lipoprotein(α) in plasma

15:55 – 17:25 Coffee break and Guided Poster Session

- 17:25 – 18:55 **WS4: Epidemiology of Lp(α)**
Chairs: Gerd Utermann, Santica Marcovina
- 17:25 **Pia Kamstrup** (Herlev, DK)
Lp(α) in type 2 diabetes, aortic valve stenosis, and heart failure
- 17:55 **Ernst J. Schaefer** (Boston, USA)
Lipoprotein(α) and cardiovascular disease risk
- 18:25 **Mary Seed** (London, UK)
Lipoprotein(α) improves CHD risk discrimination in UK healthy middle aged men: data from year 10 of the 2nd Northwick Park Heart Study
- 18:35 **Anne Langsted** (Herlev, DK)
High lipoprotein(α) as a cause of clinical familial hypercholesterolemia
- 18:45 **Albert Wiegman** (Amsterdam, NL)
Lp(α) as high in children with heterozygous FH as in unaffected sibs
- 18:55 **End of scientific program**

19:30 – 24:00 **Social evening**

The social event will be hosted at an alpine mountain hut close by. Please book your ticket online via the conference webpage.



Buses will depart from the conference venue at 19:00. After a short ride we will arrive at the mountain base, where a cable car will bring us to the alpine hut (1.600 meters above sea level). Traditional Tyrolean food (including Tyrolean vegetarian options) will be available (buffet style).

Please notice:

As the dinner will take place at an alpine mountain hut, appropriate clothing is required:

- * (smart) casual warm clothing
- * no high heels, no dinner jacket

Buses will bring us back to the conference venue starting at 22:30.

- 8:30 – 10:00 **WS5: Importance of Lp(a) in various clinical conditions**
Chairs: Alberico Catapano, Pia Kamstrup
- 8:30 **Karam Kostner** (Brisbane, AU)
Clinical view of the practitioner
- 9:00 **Peter Willeit** (Cambridge, UK)
Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study
- 9:10 **Benoit Arsenault** (Quebec, CA)
Ideal cardiovascular health influences cardiovascular disease risk associated with high lipoprotein(a) levels and genotype: the EPIC-Norfolk Study
- 9:20 **Elena Sticchi** (Florence, IT)
Apolipoprotein(a) kringle-IV type 2 copy number variation is associated with venous thromboembolism
- 9:30 **Marat Ezhov** (Moscow, RU)
Lipoprotein(a) is associated with short and long-term cardiovascular events after CABG
- 9:40 **Christoph Waldeyer** (Hamburg, GE)
Lipoprotein(a) as a cardiovascular risk factor in the European BiomarCaRE population
- 9:50 **Anne Langsted** (Herlev, DK)
PCSK9 R46L loss-of-function mutation reduces lipoprotein(a), LDL cholesterol and risk of aortic valve stenosis
- 10:00 – 10:30 Coffee break

- 10:30 – 11:50 **WS6: Therapy of elevated Lp(a)**
Chairs: John Chapman, Karam Kostner
- 10:30 **Alberico Catapano** (Milan, IT)
Are PCSK-9 inhibitors recommended for lowering Lp(a)?
- 11:00 **Gerald Watts** (Perth, AU)
Sustained effect of PCSK9 inhibition with alirocumab on serum lipoprotein(a) levels
- 11:30 **Julian Van Capelleveen** (Amsterdam, NL)
Effect of potent lipoprotein(a) lowering with IONIS-APO(a)-LRx on monocyte migration and monocyte inflammatory response
- 11:40 **Reinhard Klingel** (Cologne, DE)
Lipoprotein apheresis for isolated Lp(a)-hyperlipoproteinemia and progressive cardiovascular disease – 5 years results of the Pro(a)LiFe study
- 11:50 – 13:40 Lunch break

12:00 – 13:30 **LUNCH SYMPOSIUM**
Hyperlipoprotein(α)emia –
HOW BIG IS THE PROBLEM?
Epidemiology and clinical implications

(supported by Fresenius Medical Care and
 Kaneka Pharma Europe N.V.)

*Chairs: Elisabeth Steinhagen-Thiessen,
 Kurt Derfler*

- 12:00 **Florian Kronenberg** (Innsbruck, AT)
**Lp(α): epidemiological data on the
 general population**
- 12:15 **Bernd Hohenstein** (Dresden, DE)
**Introduction of Lp(α) apheresis –
 what we know and need**
- 12:25 **Ulrich Julius** (Dresden, DE)
New thoughts on Lp(α) apheresis
- 12:40 **Klaus-Peter Mellwig** (Bad Oeynhausen, DE)
**Lp(α) and Lp(α) apheresis from the
 perspective of cardiologists**
- 12:50 **Wolfgang Ramlow** (Rostock, DE)
**Cardiometabolic risk assessment –
 a challenge in daily routine**
- 13:05 **Panel discussion**

- 13:40 – 15:10 **WS7: Methodology: when, how and
 what to measure?**
Chairs: Gert Kostner, Børge Nordestgaard
- 13:40 **Santica Marcovina** (Seattle, USA)
**Standardization of methods for measuring
 Lp(α): what has been achieved and what
 needs to be done?**
- 14:10 **Florian Kronenberg** (Innsbruck, AT)
**Lp(α) measurement: a potpourri of
 problems**
- 14:40 **Hubert Scharnagl** (Graz, AT)
**Survey of commercial kits for Lp(α)
 quantification in the clinical laboratory**
- 15:00 **Ingrid Zegers** (Geel, BE)
**Requirements of a certified reference
 material**
- 15:10 – 15:40 Coffee break
- 15:40 – 16:10 **Best presentation awards**

16:10 – 17:40 **Round table discussion with invited speakers and patient representatives**

16:10 **Part I (Basic Science)**

Chair: Gert Kostner

- Genetics, Metabolism, Pathophysiology
- Epidemiology
- Efficacy of new drugs
- Methodology, Reference Material, Assay harmonization

17:00 **Part II (Clinical aspects)**

Chair: Florian Kronenberg

- What is the real risk of Lp(a)?
- How far are we from bedside?
- Is it time for intervention studies?
- Guidelines: what should be addressed?
- View of patient organizations
(Lipoproteinafoundation, FHchol Austria and CholCo)

Platin Sponsoring

デンカ生研(株)

DENKA SEIKEN CO., LTD.

Silver Sponsoring



Partner Companies



Partner Organisations




EAS



Lipoprotein *a*™
FOUNDATION

International



Lp(a) Satellite Meeting

From Bench to Bedside
Innsbruck, May 27-28, 2016

Together with our partners
we look forward to meeting you
in the center of the Alps at the
International Lp(a) Satellite Meeting
held in Innsbruck, Austria May 27-28, 2016.

<http://lpa.i-med.ac.at>